New Approvals, Biosecurity In Spotlight As China Gears For National Congress
Proposed Law Gains Momentum Post-COVID-19
Executive Summary
China grants new approvals to multiple new drugs for cancer and rare diseases, as the government gears up to hold its delayed annual congress in Beijing, attended by thousands of delegates who will vote on key new biosecurity legislation as the pandemic appears to be receding in the country.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.